Biotage (BIOT.ST) Stock Price
Biotage Price
Revenue has compounded at 8.6% per year over the past 19 years to 2.06 B SEK. Earnings per share have grown at 30.0% per year over the last 18 years. Biotage's net margin stands at 13.8%, down from 16.0% several years earlier. Biotage currently offers a dividend yield of about 1.12%. The payout ratio is around 45% of earnings. The dividend has grown at 14.9% per year over the past 15 years.
Biotage stock price
Biotage business model & stock analysis
Frequently asked questions about Biotage
Biotage AB operates under a business model focused on providing innovative separation solutions for pharmaceutical, biotech, and academic research organizations. The company specializes in the development, manufacturing, and distribution of instruments, consumables, and software for analytical chemistry, medicinal chemistry, and process development. Biotage's products enable efficient sample preparation, purification, and analysis, leading to improved productivity and quality in various applications. With a strong emphasis on customer-driven solutions, Biotage aims to support researchers and industry professionals in their quest for reliable and efficient chemical analysis and purification techniques. Biotage AB remains dedicated to advancing science and delivering superior products to meet the evolving needs of the life sciences industry.
Biotage AB is primarily active in the life sciences and pharmaceutical industries.
The main competitors of Biotage AB in the market include Agilent Technologies Inc., Thermo Fisher Scientific Inc., and Shimadzu Corporation. These companies provide similar products and services in the field of analytical chemistry, separation science, and purification technologies. Biotage AB competes with these industry leaders by offering innovative solutions and a wide range of products such as chromatography systems, purification systems, and consumables. With its dedication to research and development, Biotage AB strives to stay competitive and deliver cutting-edge solutions that meet the needs of its customers.
Biotage AB is a well-established company in the field of life sciences and analytical chemistry. It was founded in 2003 and has since become a leading provider of tools and solutions for organic and analytical chemistry. Biotage AB specializes in the development and production of products used in research, drug discovery, and quality control applications. With a strong focus on innovation and customer satisfaction, Biotage AB offers a wide range of solutions, including purification systems, sample preparation, and analytical instruments. The company has a global presence, serving customers in various sectors such as pharmaceutical, biotechnology, and academia. Biotage AB continues to strive for excellence in delivering high-quality products and driving advancements in the field of life sciences.
Biotage AB has achieved several significant milestones. The company has successfully developed and introduced innovative solutions in the field of separation sciences, including purification systems, sample preparation, and analysis tools. It has also expanded its product portfolio by acquiring complementary technologies and businesses, thereby strengthening its market position. Biotage AB has demonstrated steady revenue growth and profitability over the years, reflecting its successful market strategies. Additionally, the company has fostered strong collaborations with leading research institutions and industry partners, enabling them to provide cutting-edge solutions to their customers. Biotage AB's dedication to innovation and customer satisfaction has propelled its success in the stock market.
Biotage AB is primarily present in several countries and regions worldwide. The company has a strong presence in Europe, including Sweden, where its headquarters are located. Biotage AB also has operations in other European countries such as Germany, United Kingdom, France, Italy, and Spain. Additionally, Biotage has established a significant presence in North America, particularly in the United States. With its global reach, Biotage AB is continually expanding its market presence and serving customers in diverse regions around the world.
Biotage AB is committed to upholding a set of core values and a corporate philosophy that guide its operations. The company values innovation, excellence, and the pursuit of sustainable solutions for its customers. Biotage AB focuses on developing cutting-edge technology to support scientists and researchers in their pursuit of breakthroughs. With a customer-driven approach, the company aims to deliver reliable and high-quality products and services that meet the evolving needs of the scientific community. Additionally, Biotage AB prioritizes social responsibility by adhering to ethical practices, promoting diversity and inclusion, and minimizing its environmental impact.
10 analysts currently rate the Biotage stock: 0 recommend buying, 4 holding and 6 selling. For 2026, analysts expect Biotage to generate revenue of 2.07 B SEK and earnings per share of 4.25 SEK.
Converted at the current exchange rate, the Biotage share trades at 12.79 EUR (143.20 SEK).
The Biotage share (BIOT.ST) is listed on 7 stock exchanges, including: London (0GRP.L), Frankfurt (PQX1.F), München (PQX1.MU), Düsseldorf (PQX1.DU), Stockholm (BIOT.ST).
Biotage AB is a leading company in the field of separation technology and offers innovative solutions for the purification of chemical compounds in the pharmaceutical, biotechnological, and chemical industries, as well as in the food and environmental industries. The company Biotage specializes in three business areas: separation technology, analytical instruments, and consumer products. In the field of separation technology, Biotage offers a wide range of products, including solid phase extraction, flash chromatography, air particle removal, and ion exchange resins. These products are used in the chemical and biotechnological industries to separate and purify compounds. In the field of analytical instruments, Biotage produces high-performance chromatography systems, mass spectrometers, and spectroscopy systems. These instruments are used in scientific research and quality control in the pharmaceutical and biotechnological industries. In the field of consumer products, Biotage offers a wide range of products, including reagents, laboratory supplies, and consumables. The flagship product of the company in the field of separation technology is the Isolera™ Prime Flash Chromatograph. This instrument uses patented technology to perform fast and effective separations in the chemical and biotechnological industries. Biotage's top-of-the-line analytical instrument is the nau-MS™ system, which combines the performance of a mass spectrometer with the speed and efficiency of flash chromatography. The nau-MS™ system allows scientists and researchers to quickly and easily identify and quantify compounds in complex samples. Biotage also produces a wide range of portable GC-MS systems and TOF-MS systems, which are used in healthcare monitoring, environmental monitoring, forensic science, and the food industry. Biotage's products are used by leading companies in the pharmaceutical, biotechnological, and chemical industries, as well as in environmental monitoring and the food industry. Biotage's customers include Novartis, Pfizer, Merck, Johnson & Johnson, Roche, AstraZeneca, GlaxoSmithKline, and Sanofi. Biotage is headquartered in Uppsala, Sweden, and has offices and sales offices in North America, Europe, and Asia. The company has a strong presence in the United States, the largest market for separation technologies. In recent years, the company has expanded its product range through strategic acquisitions. In 2017, Biotage acquired the German flash chromatography specialist Interchim, and in 2019, it acquired the American company PhyNexus. These acquisitions have strengthened Biotage's position in the market for separation technology and analytical instruments. In conclusion, Biotage is a leading company in the field of separation technology and analytical instruments, providing a wide range of products and solutions for its customers. The company has a strong presence in the markets of the pharmaceutical, biotechnological, and chemical industries, as well as the environmental and food industries, and is on a growth trajectory through strategic acquisitions and global expansion.
The expected revenue of Biotage is 2.07 B SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Biotage is 340.82 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Biotage is currently 33.68. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biotage stock.
The price-to-sales ratio (P/S) of Biotage is currently 5.55. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biotage stock.
The Eulerpool Quality Score for Biotage is 8/10.
The ISIN of Biotage is SE0000454746. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biotage is A0MNB5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biotage is BIOT.ST. The ticker symbol is used to trade Biotage shares on the stock exchange.
Biotage stock
All fundamentals and in-depth analysis of Biotage
Our stock analysis for Biotage stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotage. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.